Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:23:53.525Z.
Calculation as of: 2026-10-06T22:23:53.525Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0deb7c30adcc78f114172cbc577a9cc7a44fb527f6444d978a27313071d44bdc
PE RATIO
N/A
Market Cap
$17.31M
PE Ratio
N/A
TTM Avg
29275707116178676.00
3Y Avg
6105628756850110.00
5Y Avg
6105628756850110.00
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TScan Therapeutics, Inc. (TCRX) | $16.82M | N/A | N/A | N/A | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | N/A | N/A | N/A | N/A |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | N/A | 6.43 | 6.43 | 6.43 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | N/A | N/A | N/A | N/A |
| PAVmed Inc. (PAVM)vs › | $17.07M | N/A | 0.60 | 0.60 | 0.60 |
| Dyadic International, Inc. (DYAI)vs › | $16.52M | N/A | 0.84 | 0.84 | 28.37 |
| Lipocine Inc. (LPCN)vs › | $17.31M | N/A | 29275707116178676.00 | 6105628756850110.00 | 6105628756850110.00 |
| Cosmos Health Inc. (COSM)vs › | $17.39M | N/A | 49.08 | 49.08 | 49.08 |
| BioCardia, Inc. (BCDA)vs › | $15.78M | N/A | 42.19 | 43.76 | 41.41 |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.68M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.28
Forward EPS (Est.)
$-0.80
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
